Sarcopenia is a cause of muscle atrophy. The prevalence of sarcopenia increases with age, ranging from 5-13% in 60-70 years old to 11-50% in people over 80 years old. The literature confirms that sarcopenia is associated with adverse clinical outcomes such as disability, institutional occupancy, falls, injuries, hospitalizations, and complete slow or inability to recover from the disease leading to death. Therefore, how to treat patients with sarcopenia in later stages or those who fall into sarcopenia because of medical treatment, develop drug therapy to increase muscle mass and strength, improve patients' quality of life and survival rate, is an urgent but not yet received met medical needs.

According to past research, stem cells have the function of tissue regeneration, and stem cell transplantation may have the potential to be an important way to improve muscle atrophy caused by sarcopenia.

In this study, we assessed the effect of adipose-derived stem cells (ADSCs) on muscle differentiation and muscle atrophy in vitro through undifferentiated C2C12 muscle cells, by observing cell morphology, immunofluorescence staining and using qPCR. To evaluate whether ADSCs has the ability to promote the differentiation of mouse skeletal muscle cells, and to use Dexamethasone to induce atrophy of differentiated C2C12 myotube cells, so as to establish a cell model of muscle atrophy. By observing the morphology of muscle cells and using qPCR to detect and analyze the changes in muscle regeneration.

Stem cell therapy technology is gradually moving from basic research to clinical application. This project presents the impact of ADSCs in sarcopenia causing muscle atrophy.